CategoryLab Lessons

Will a sugar diet sort out progressive MS.

This week media stories have surfaced that a diet of plant sugar will deal with progressive MS because it rejuvenates the microglia to clear nerve debris away to promote recovery. Great we say. This study identifies a trigger factor called ATG7 . The Autophagy related 7 protein acts as an essential protein for cell degradation and its recycling. But we know this already based on loads of studies...

Will the mechanistic SH1 ever stick? or will we have more failed MS studies?

Today is hard core science day. We can learn a bit together. You can learn a lot for the human experiment, which is the clinical trial. Success of trial points the finger at something important, but failure can too. We thought what works in arthritis (MS of the Joint) would work in MS (arthritis of the brain). That was until we tried tumour necrosis factor (TNF) inhibitory activity. It is...

#Smouldering-MS: the BTK inhibitor race is on

Barts-MS rose-tinted-odometer: ★★★ Mouse Doctor studied zoology and as a result, he tends to use animal analogies to describe various phenomena. In the past, he has been known to use his favourite invertebrates to describe some neurologists or even groups of neurologists. Why invertebrates? If anyone comes up with the correct answer I will send you an MRI scanner lego set as a prize. ...

Brain microglial activity predicts faster progression of MS

Prof Laura Airas is based in Turku PET Centre, Turku, Finland and writes about their recent paper. Disclosures  She has received honoraria from Biogen, Roche., Genzyme, Merck Serono and Teva, and institutional research grant support from Finnish Academy, Sigrid Juselius Foundation, Nancy Davis Foundation, Biogen, Genzyme, Merck Serono and Novartis. Prof Laura Airas writes Brain microglial...

Smouldering MS: Is 20 years a long time?

Barts-MS rose-tinted-odometer: zero stars or one ★ depending on your disposition I prepared this post not knowing that Prof. Laura Airas has submitted a guest post in response to a request from the Mouse Doctor. Before reading this post please make sure you read her blog post first. It provides an important counterbalance to my contrarian view below. Thank you. More than 20 years ago, when I was...

Plot thickens: MS versus other antibody disorders

The MSVirtual2020 late breaking news was announced this weekend. Despite a diagnostic biomarker for neuromyelitis optica (the Aquaporin 4 antibody), it remains difficult differentiate NMO from MS clinically. Dr David Leppert from Basel, Switzerland presented their findings on biomarkers of the innate immune system, focusing on neutrophil activity markers (a type of immune cell) in the...

CD20 The Next Generation. Will they be neuroprotective?

Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?Reddy V, Dahal LN, Cragg MS, Leandro M.Drug Discov Today. 2016 Aug;21(8):1330-8.  In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using rituximab results in variable clinical responses between individuals, which likely relates to variable B-cell depletion in...

Remyelination here we come…well almost. Bexarotene trial ECTRIMS

The basic science gives the tools for the clinicians to try and find treatments and Prof Franklinstein (Robin Franklin) from Cambridge and Prof ffffffffffrench-constant from Edinburgh hunted for molecules that may affect switches from precursors cells to full myelinating cells. They came up with a target that is triggered by the retinoid X receptor (RXR) gamma. Prof Franklin tried to get...

T cells in MS brain

The central nervous system (CNS) features mechanisms to protect against untoward inflammation yet allowing immune surveillance for pathogens. Pappalardo et al. profiled T cells in the cerebrospinal fluid (CSF) of healthy individuals and patients with multiple sclerosis (MS) using single-cell RNA and TCR sequences to define CNS immune homeostasis in both healthy and patients with MS. In...

Beyond NEDA: protecting the end-organ or your brain

Barts-MS rose-tinted-odometer: zero-★’s  It became clear to me at least 6 years ago that we need to go beyond NEDA (no evident disease activity) when treating MS and we have to focus on protecting the end-organ, i.e. normalising the brain volume loss that occurs in people with MS (pwMS). To do this you really need to diagnose and treat MS as effectively as possible early on. From a research...

Translate

Categories

Recent Posts

Recent Comments

Archives